Lucky you. I bought much higher... The only news coming from these losers is bankruptcy... They only have enough money to make it until June...
The clinical benefits of chemotherapy are commonly offset by insufficient drug exposures, narrow safety margins, and/or systemic toxicities. Over recent decades, a number of conjugate-based targeting approaches designed to overcome these limitations have been explored. Here, we report on an innovative strategy that utilizes HSP90 inhibitor-drug conjugates (HDC) for directed tumor targeting of chemotherapeutic agents. STA-12-8666 is an HDC that comprises an HSP90 inhibitor fused to SN-38, the active metabolite of irinotecan. Mechanistic analyses in vitro established that high-affinity HSP90 binding conferred by the inhibitor backbone could be exploited for conjugate accumulation within tumor cells. In vivo modeling showed that the HSP90 inhibitor moiety was required for selective retention of STA-12-8666, and this enrichment promoted extended release of active SN-38 within the tumor compartment. Indeed, controlled intratumoral payload release by STA-12-8666 contributed to a broad therapeutic window, sustained biomarker activity, and remarkable degree of efficacy and durability of response in multiple cell line and patient-derived xenograft models. Overall, STA-12-8666 has been developed as a unique HDC agent that employs a distinct mechanism of targeted drug delivery to achieve potent and sustained antitumor effects. These findings identify STA-12-8666 as a promising new candidate for evaluation as novel anticancer therapeutic. Mol Cancer Ther; 14(11); 2422-32. ©2015 AACR
Sentiment: Strong Buy
Can you post the link where you found this? I was holding out for .18 but now I'm doubting if it will go that low.
Background: Small cell lung cancer (SCLC) is a lethal disease, with 5 year survival of only 6%. While patients initially respond to cytotoxic chemotherapies, resistance rapidly emerges and response to second line agents is limited. STA-12-8666 is a small molecule, which binds the tumor-concentrated active form of heat shock protein 90 (HSP90), with a cleavable linker attached to SN-38, the active metabolite of irinotecan. Cleavage of the linker within the tumor provides time-release of SN-38 at high local concentration, limiting drug exposure and toxicity in normal issue. We evaluated STA-12-8666 for use as a new effective cancer therapy. Methods: Three dose levels of STA-12-8666 were evaluated in comparison to irinotecan, ganetespib, carboplatin, etoposide, topotecan and chemotherapy combinations in xenograft models including SCLC cell lines, patient derived xenografts (PDXs), and chemotherapy-refractory SCLC model. Intratumoral responses were profiled using a mass spectrometry approach to evaluate kinase pathway activation, and results confirmed by immunohistochemistry and western blot. Pharmacokinetic analysis was performed for STA-12-8666 comparing to isomolar irinotecan. Results: The data suggest exceptional potency of high dose (150 mg/kg) STA-12-8666 as a monoagent in multiple SCLC models, with three weekly doses resulting in clearance of palpable tumors, durable effect ( 2 months). Low dose STA-12-8666 (50 mg/kg) substantially augmented the activity of carboplatin. Higher dose STA-12-8666 was effective at controlling or eliminating tumors pre-treated with and resistant to irinotecan, topotecan or platinum. Tumors recurring in mice previously treated with STA-12-8666 remained sensitive to 150 mg/kg and were eliminated upon re-treatment. No weight loss or toxicities were observed. Profiling of tumors treated with STA-12-8666 showed robust induction of intratumoral toxicity, and candidate response biomarkers relevant to DNA damage response and other processes
Sentiment: Strong Buy
I've been following trade alerts from the Penny Stock 101 org newsletter, and I've been consistanly beating the market. If you want to get an early jump on the fastest moving NASDAQ, NYES and OTC stocks signup now.Just on an email stating they have a new pick coming tomorrow!
Are you a miserable trader? Change it around by joining ULTIMATE STOCK ALERTS (google em) today! They only alert Nasdaq and nyse stocks with nice charts and good catalysts. You wont be sorry if you join.
I think the key is how the insiders play this. Also, at .26 a share it is fire sale pricing. Oncology panel should have some summation as well.
Sentiment: Strong Buy
EOP was formed few days before the band news came out. I really think everyone at Synta was shocked with PIII data. In my opinion EOP was setup to guide the company with positive data. With negative data, EOP is useless.
Incidently, now we know that when a company we are invested in announces the formation of an expert scientific panel to assist them, then you sell every single share immediately because it means they do not know what the heck they are doing.
There is always hope. I bought into this exactly one day before they announced failure so I will stay until it goes to zero or bounces substantially because there really is no other course of action after taking that kind of hit. We are all just sick about it but if their other trials demonstrate even a small amount of success, then we should see the $1 range by the end of the year. I will stay for the long haul - this is one of those investments that I have virtually already written off to zero so any improvements from here are golden. BTW, I am at 89% down.
Check out ULTIMATE STOCK ALERTS (search them on google) and you wont be disappointed. Their last alert made me 30% over 3 days. Cant complain about that, especially in such a bearish market.
Looks to me like SNTA will have (as of year end) about 45-50 cents per share of net cash (after subtracting real liabilities). Burn rate has been cut substantially going forward, as they stated in last PR that this would last them at least through half of 2017.
In the meantime, besides the usual reverse merger type catalyst, there appear to be 4 trials still ongoing that could report results in this time window (see below)
. Synta continues to support enrollment in four additional large, randomized, multi-center investigator-sponsored studies, including: the GANNET53 trial of ganetespib and paclitaxel in ovarian cancer; the AML LI-1 trial of ganetespib with low dose cytarabine (Ara-C) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); the AML18 trial of ganetespib with standard DA (daunorubicin and Ara-C) in AML and high-risk MDS; and the I-SPY 2 TRIAL of ganetespib and standard chemotherapy in women with newly diagnosed, locally advanced breast cancer.
Looks like a very nice risk/reward for 23 cents a share.
Is there any hope here for a recovery? Yahoo Finance has a $8 price target and we're sitting at $0.23. My investment is down 92% but I'm still holding for a rebound. Am I crazy? Probably, but if I sell now, I will centainly lose 92%; if I hold on perhaps we can get back in the black but we will need some kind of guidance out of this "expert oncology panel!" C'mon EOP, say something that will save your #$%$ and the rest of us fools that bot into SNTA on the hope that your products will be of benefit to mankind and also to make some money!